MR imaging of liver fibrosis: Current state of the art

Radiographics

Volumn 29, Issue 6, 2009, Pages 1615-1635

  Faria, Silvana C ^a,c   Ganesan, Karthik ^a   Mwangi, Irene ^a   Shiehmorteza, Masoud ^a   Viamonte, Barbara ^a   Mazhar, Sameer ^b   Peterson, Michael ^a   Kono, Yuko ^b   Santillan, Cynthia ^a   Casola, Giovanna ^a   Sirlin, Claude B ^a  

^a UCSD MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; IMAGE ENHANCEMENT; LIVER; LIVER CIRRHOSIS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW;

HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING;

EID: 77449088122     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.296095512     Document Type: Article

References (50)

1. Friedman SL. Hepatic fibrosis: overview. Toxicology 2008;254(3):120-129.
2. Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem Genet 2008;411(1):1-18.
3. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99(6): 1160-1174.
4. Jou JH, Muir AJ. In the clinic: hepatitis C. Ann Intern Med 2008;148(11):ITC6-1-ITC6-16.
5. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009;49(1):306-317.
6. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371(9615):838-851.
7. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007;128(5): 837-847.
8. Wanless IR, Crawford JM. Cirrhosis. In: Odze RD, Goldblum JR, Crawford JM, eds. Surgical pathology of the GI tract, liver, biliary tract, and pancreas. Philadelphia, Pa: Elsevier, 2004; chap 37.
9. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20(1 pt 1):15-20.
10. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696-699.
11. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995;19(12):1409-1417.
12. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94 (9):2467-2474.
13. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2005;41(6):1313-1321.
14. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42(3):641-649.
15. Thiese ND, Bodenheimer HC, Ferrell LD. Acute and chronic viral hepatitis. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween's pathology of the liver. 5th ed. Edinburgh, Scotland: Churchill Livingstone, 2006; chap 8.
16. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118(2):96-98.
17. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97(10):2614-2618.
18. Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996;43(6):568-571.
19. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39(2): 239-244.
20. Dodd GD 3rd, Baron RL, Oliver JH 3rd, Federle MP. Spectrum of imaging findings of the liver in end-stage cirrhosis. I. Gross morphology and diffuse abnormalities. AJR Am J Roentgenol 1999;173 (4):1031-1036.
21. Dodd GD 3rd, Baron RL, Oliver JH 3rd, Federle MP. Spectrum of imaging findings of the liver in end-stage cirrhosis. II. Focal abnormalities. AJR Am J Roentgenol 1999;173(5):1185-1192.
22. Ito K, Mitchell DG. Imaging diagnosis of cirrhosis and chronic hepatitis. Intervirology 2004;47(3-5): 134-143.
23. Martin DR. Magnetic resonance imaging of diffuse liver diseases. Top Magn Reson Imaging 2002;13 (3):151-163.
24. Ito K, Mitchell DG, Siegelman ES. Cirrhosis: MR imaging features. Magn Reson Imaging Clin N Am 2002;10(1):75-92.
25. Brancatelli G, Federle MP, Ambrosini R, et al. Cirrhosis: CT and MR imaging evaluation. Eur J Radiol 2007;61(1):57-69.
26. Bydder M, Yokoo T, Hamilton G, et al. Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging 2008;26(3): 347-359.
27. Yokoo T, Bydder M, Hamilton G, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled- echo MR imaging at 1.5 T. Radiology 2009; 251(1):67-76.
28. Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol Clin North Am 2005; 43(5):887-898.
29. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol 1990;155(5):943-950.
30. Lucidarme O, Baleston F, Cadi M, et al. Noninvasive detection of liver fibrosis: is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur Radiol 2003;13(3): 467-474.
31. Ward J, Robinson PJ. Combined use of MR contrast agents for evaluating liver disease. Magn Reson Imaging Clin N Am 2001;9(4):767-802.
32. Helmberger T, Semelka RC. New contrast agents for imaging the liver. Magn Reson Imaging Clin N Am 2001;9(4):745-766.
33. Hughes-Cassidy F, Chavez AD, Schlang A, et al. Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis. J Magn Reson Imaging 2007;26(3):728-737.
34. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006;239(2):425-437.
35. Manduca A, Oliphant TE, Dresner MA, et al. Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal 2001; 5(4):237-254.
36. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance im-aging of hepatic fibrosis: emerging clinical applications. Hepatology 2008;47(1):332-342.
37. Rouvière O, Yin M, Dresner MA, et al. MR elastography of the liver: preliminary results. Radiology 2006;240(2):440-448.
38. Yin M, Talwalkar JA, Glaser KJ, et al. A preliminary assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5(10):1207-1213.
39. Bensamoun SF, Wang L, Robert L, Charleux F, Latrive JP, Ho Ba Tho MC. Measurement of liver stiffness with two imaging techniques: magnetic resonance elastography and ultrasound elastometry. J Magn Reson Imaging 2008;28(5):1287-1292.
40. Souchon R, Salomir R, Beuf O, et al. Transient MR elastography (t-MRE) using ultrasound radiation force: theory, safety, and initial experiments in vitro. Magn Reson Med 2008;60(4):871-881.
41. Mariappan YK, Rossman PJ, Glaser KJ, Manduca A, Ehman RL. Magnetic resonance elastography with a phased-array acoustic driver system. Magn Reson Med 2009;61(3):678-685.
42. Lewin M, Poujol-Robert A, Boëlle PY, et al. Diffusion- weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007;46(3):658-665.
43. Taouli B, Martin AJ, Qayyum A, et al. Parallel imaging and diffusion tensor imaging for diffusionweighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol 2004; 183(3):677-680.
44. Taouli B, Tolia AJ, Losada M, et al. Diffusionweighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007; 189(4):799-806.
45. Boulanger Y, Amara M, Lepanto L, et al. Diffusionweighted MR imaging of the liver of hepatitis C patients. NMR Biomed 2003;16(3):132-136.
46. Hagiwara M, Rusinek H, Lee VS, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 2008;246(3):926-934.
47. Miyazaki S, Yamazaki Y, Murase K. Error analysis of the quantification of hepatic perfusion using a dual-input single-compartment model. Phys Med Biol 2008;53(21):5927-5946.
48. Caravan P, Das B, Dumas S, et al. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl 2007;46(43): 8171-8173.
49. Caravan P. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 2009 Feb 17. [Epub ahead of print]
50. Beljaars L, Meijer DK, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002;7:e214-e222.